CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company
developing T cell-directed vaccines and immunotherapies, today announced
the pricing of its public offering of 5,454,545 shares of its common
stock at a public offering price of $8.25 per share, before underwriting
discounts. In addition, Genocea has granted the underwriters a 30-day
option to purchase up to an additional 818,181 shares of common stock at
the same price. The offering is expected to close on or about March 17,
2015, subject to satisfaction of customary closing conditions.
Cowen and Company and Piper Jaffray & Co. are acting as joint
book-running managers for the offering. Stifel is acting as lead manager
and Needham & Company is acting as co-manager.
The offering is being made pursuant to an effective shelf registration
statement on Form S-3 filed with the Securities and Exchange Commission
(the "SEC") on March 2, 2015, and a related final prospectus supplement
filed on March 12, 2015. Before you invest, you should read the
prospectus in the registration statement and related preliminary
prospectus supplement that Genocea. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy and
there shall not be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities
laws of any such state or jurisdiction.
The preliminary prospectus supplement is available for free by visiting
EDGAR on the SEC's website located at www.sec.gov.
Copies of the preliminary prospectus supplement and final prospectus
supplement may also be obtained from Cowen and Company c/o Broadridge
Financial Services, Attention: Prospectus Department, 1155 Long Island
Avenue, Edgewood, NY 11717, by calling (631) 274-2806, or by fax (631)
254-7140 or Piper Jaffray & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, by calling (800) 747-3924,
or by emailing email@example.com.
About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop
life-changing vaccines and immunotherapies. T cells are increasingly
recognized as a critical element of protective immune responses to a
wide range of diseases, but traditional discovery methods have proven
unable to identify the targets of such protective immune response. Using
ATLAS™, its proprietary technology platform, Genocea identifies these
targets to potentially enable the rapid development of medicines to
address critical patient needs. Genocea's pipeline of novel clinical
stage T cell-enabled product candidates includes GEN-003 for HSV-2
therapy, GEN-004 to prevent infections caused by pneumococcus, and
earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and
This press release includes forward-looking statements, including
statements relating to the proposed underwritten public offering. Such
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statements. Genocea cautions that these forward-looking
statements are subject to numerous assumptions, risks and uncertainties,
which change over time. Applicable risks and uncertainties include those
identified under the heading "Risk Factors" included in Genocea's Annual
Report on Form 10-K for the year ended December 31, 2014 and any
subsequent SEC filings, including the registration statement and final
prospectus supplement related to the proposed offering. These
forward-looking statements speak only as of the date of this press
release and Genocea assumes no duty to update forward-looking statements.
Spectrum Science Communications
Lustig, O: 202-955-6222
Genocea Biosciences, Inc.
Jonathan Poole, O:
Source: Genocea Biosciences, Inc.
News Provided by Acquire Media